Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 January 2015Website:
http://opusgtx.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 30 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
What type of business is Opus Genetics?
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
What sector is Opus Genetics in?
Opus Genetics is in the Healthcare sector
What industry is Opus Genetics in?
Opus Genetics is in the Biotechnology industry
What country is Opus Genetics from?
Opus Genetics is headquartered in United States
When did Opus Genetics go public?
Opus Genetics initial public offering (IPO) was on 19 January 2015
What is Opus Genetics website?
https://opusgtx.com
Is Opus Genetics in the S&P 500?
No, Opus Genetics is not included in the S&P 500 index
Is Opus Genetics in the NASDAQ 100?
No, Opus Genetics is not included in the NASDAQ 100 index
Is Opus Genetics in the Dow Jones?
No, Opus Genetics is not included in the Dow Jones index
When was Opus Genetics the previous earnings report?
No data
When does Opus Genetics earnings report?
The next expected earnings date for Opus Genetics is 13 November 2024